You are here

  • Home
  • Archive
  • Volume 63, Issue 9
  • Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artifactual result of research methodology?

Article Text

Article menu
Download PDFPDF
Commentary
Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artifactual result of research methodology?
  1. Basile Njei
  1. Correspondence to Dr Basile Njei, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-1845, USA; basilenjei{at}gmail.com

https://doi.org/10.1136/gutjnl-2013-306333

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Among the primary hepatic malignant tumours, hepatocellular carcinoma (HCC) is the most common, while fibrolamellar carcinoma is a rare variant of HCC. In a recent article by Eggert et al examining the epidemiology of fibrolamellar hepatocellular carcinoma (fHCC) in the USA from 2000 to 2010,1 the authors reported better 5-year survival for fHCC compared with conventional HCC similar to previous studies.2–⇓⇓⇓⇓7 Even though several previous studies have advocated that fHCC is less aggressive than conventional HCC, some recent studies have failed to confirm the observation of a better outcome in fHCC.8–⇓⇓11 Cirrhosis is a well …

    View Full Text

    Footnotes

    • Funding None.

    • Contributors BN conceived the idea, carried out the data analysis and wrote the manuscript.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles